Next Article in Journal / Special Issue
When Prostate Cancer Circulates in the Bloodstream
Previous Article in Journal
Scintigraphic Small Intestinal Transit Time and Defaecography in Patients with J-Pouch
Previous Article in Special Issue
Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
Article Menu

Export Article

Open AccessArticle
Diagnostics 2015, 5(4), 413-427; doi:10.3390/diagnostics5040413

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT

1
Departments of Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, Saukonpaadenranta 2, Helsinki FI-00180, Finland
2
Departments of Radiotherapy and Medical Oncology, Docrates Cancer Center, Saukonpaadenranta 2, Helsinki FI-00180, Finland
Present Address: Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, 1400 Pressler, Houston, TX 77030, USA.
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen Assinder
Received: 21 August 2015 / Revised: 25 September 2015 / Accepted: 29 September 2015 / Published: 13 October 2015
(This article belongs to the Special Issue Prostate Cancer Diagnosis)
View Full-Text   |   Download PDF [2206 KB, uploaded 13 October 2015]   |  

Abstract

The purpose of this study was to evaluate the outcome after Radium-223-dichloride (223RaCl2) treatment of patients with skeletal metastases of castration resistant prostate cancer using whole-body 18F-Fluoride PET/CT. Sodium 18F-fluoride [18F]-NaF PET/CT was performed prior the treatment of 223RaCl2, after the first cycle and after the sixth cycle. The skeletal metastases were analyzed quantitatively using modified PET response evaluation PERCIST criteria. The patients were also analyzed for S-PSA. All ten patients responded in [18F]-NaF scans after 6 cycles, but interim analysis after the 1st cycle did not give additional information about the outcome. The S-PSA decrease correlated with [18F]-NaF response, only 1 patient demonstrated progressive disease, i.e., >25% increase in S-PSA values during 223RaCl2. Our results (although preliminary) suggest that 18F-Fluoride PET/CT is useful in the follow-up of castration resistant prostate cancer with skeletal metastases. View Full-Text
Keywords: prostate cancer; sodium fluoride; skeletal metastases; radium-223-dichloride prostate cancer; sodium fluoride; skeletal metastases; radium-223-dichloride
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kairemo, K.; Joensuu, T. Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT. Diagnostics 2015, 5, 413-427.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top